Toxicology Testing Overview

Michael E Hodsdon, MD, PhD Associate Professor of Laboratory Medicine

hodsdon.com/wiki

Drug 'Lifecycle' in Humans

Receptors Tissue Free < Bound reservoirs Absorption Free < _ _ Bound · Ingestion, Systemic circulation injection, \rightarrow Excretion Absorption inhalation, **Free Drug** Metabolites etc. (active and Protein-bound GI inactive) drug

Metabolism

- Distribution
- Metabolism
	- Metabolites usually inactive
	- **•** Determines length of efficacy
- Excretion
	- What goes in must come out
	- Usually in the urine
	- Also in feces or breath
	- Most often modified
	- Can be quite delayed

Choice of Specimen

Blood

- **Generally target active** compounds
- **Example 1 Correlates well with current** clinical effect
- **Quantitation useful (just like** therapeutic drug monitoring)
- Not that useful for detecting past use
- **Obviously, more invasive**
- Hard to adulterate

Urine

- **Generally target inactive** metabolites
- **Not specific for current use**
- Renal concentrating ability increases sensitivity
- **Detectable for days after use** (variable)
- **Quantitation varies with** hydration status; hence, generally not useful
- \blacksquare Less invasive
- Easier to adulterate

Testing Methods

Immunoassays

- **Used for screening**
- **Testing is generally automated and** results are available rapidly
- Can be instrument-based (lab) or simple 'dipstick' (bedside)
- **Sensitivity and specificity vary** greatly (dipsticks generally perform poorly)
- Less expensive
- **Commercially available but** dominated by workplace drug testing needs, not clinical

Confirmation

- **Includes HPLC, TLC, GC/MS, LC/MS/MS** (defined in handout)
- **Generally used to confirm screening** results, but can be ordered directly
- **Often relies on more complicated and** expensive equipment (but reagent costs can be less)
- **Almost always labor-intensive with** turn-around times taking days to weeks
- Sensitivity as good or better than immunoassays
- **Specificity is much better; can often** provide list of exact compounds

Enzyme-Multiplied Immunoassay Technique (EMIT)

Fig. 1. Principle of the CEDIA (cloned enzyme donor immunoassay) methodology.

(A) In the absence of free drug or drug metabolite in a urine specimen, formation of a complete tetrameric β -galactosidase enzyme is inhibited, and no product is generated after addition of substrate to the reaction mixture. (B) Drug or drug metabolite in a urine specimen competes with the enzyme donor (ED)-drug conjugate for anti-drug antibody (Ab) binding sites; complete, active β -galactosidase molecules are formed in proportion to the amount of drug or drug metabolite present, and the conversion of substrate to product is also proportional to the drug concentration in the specimen. EA, enzyme acceptor.

Detection Thresholds

- In most analyzers, antibody reactivity results in a proportional spectrophotometric signal.
	- UV/Vis absorption
	- **Fluorescence**
	- Chemiluminescence
- Each assay is calibrated using a single drug solution at a fixed concentration (e.g. 300 ng/ml morphine).
	- Reactivity greater (less) than this threshold is considered positive.
	- Reactivity less (greater) than this threshold is considered negative.
	- **Note that signal quickly becomes non-linear at concentrations above the detection threshold.**
- Many factors alter the reactivity of clinical samples.
	- Variable reactivity of similar drugs (e.g. codeine, hydrocodone, oxycodone, etc.).
	- Conjugated metabolites generally have poorer reactivity (e.g. glucuronidated opiates).
	- Unrelated cross-reacting drugs can add (or subtract) to the final signal.
	- Matrix effects: although clinical samples are diluted (1:20 1:40) into standard solutions, variations in urine components can affect final signal.
		- pH, salt concentration, protein, enzyme inhibitors, chromatographic molecules, etc.

Detection Thresholds

Opiate Detection Limits

Also need to consider

- Dosage / Dosing Interval
- Metabolism
- Urine Concentration

Opiate Metabolism

Opiate Metabolism Profiles

- *1. Pharmaceutical Morphine:* Morphine and *sometimes* oxymorphone when the morphine is very high.
- *2. Codeine:* Codeine, morphine and norcodeine/norhydrocodone (can't distinguish these two in our GC/MS method due to derivatization).
- *3. Hydrocodone:* Hydrocodone, hydromorphone and norhydrocodone/norcodeine.
- *4. Hydromorphone:* Hydromorphone.
- *5. Oxycodone:* Oxycodone and oxymorphone.
- *6. Heroin Use:* 6-monoacetylmorphine (6-MAM), morphine, codeine, and *sometimes* oxymorphone (same as with morphine).
- *7. Poppy seeds:* Morphine and codeine. Difficult to distinguish past heroin use from poppy seed ingestion. NIDA recommends the following criteria.
	- If total morphine > 5000 ng/ml (maybe 10,000 ng/ml better), or codeine > 300 ng/ml,
	- or the morphine: codeine ratio $<$ 2,
	- or total morphine > 1000 without any codeine present,
	- or the presence of any 6-MAM (specific for heroin),
	- then poppy seed ingestion is *NOT likely* the sole source of the urine opiates.

DAU Performance Summary

1) Opiates

- Detects multiple opiates with varying sensitivity.
- Poor sensitivity for oxycodone and meperidine
- Does not detect methadone, propoxyphene or fentanyl at all
- Fluoroquinolones reported to cross-react.
- 2) Methadone
	- Good sensitivity and specificity
	- Does not detect any opiate
- 3) Oxycodone
	- Very sensitive and specific
- 4) Benzodiazepines
	- Poor sensitivity for Ativan (lorazepam) and Xanax (alprazolam)
	- Good sensitivity for older benzodiazepines that are primarily metabolized to oxazepam
	- See hodsdon.com/wiki for more details, including metabolism pathways.
	- Oxaprozin (Daypro) reported to cross-react (rare)
- 1) Barbiturates
	- Good sensitivity and specificity
- 6) Cocaine (BZE)
	- Good sensitivity and specificity
- 7) Amphetamines
	- Depending on the assay, many drugs crossreact.
	- Anti-histamines most common at YNHH
- 8) Phencyclidine
	- Common cross-reactivity with dextromethorphan (metabolite)
- 9) Cannabinoids
	- Sensitivity to inactive metabolites vary; sometimes positive for weeks to months
	- Good specificity

How long should it be positive?

- Very common question, but not easy to answer.
- Two categories of research studies:
	- **Drug administered to healthy, non-abusing volunteers and urine samples** monitored (often less than 24 hours).
	- Daily urine samples collected from an inpatient drug rehabilitation facility (days to weeks).
	- **Summarized for each drug in handout.**

 Major difference is the accumulation of inactive metabolites in tissue (especially if use is much more frequent than elimination half-life, $t_{1/2}$).

 Also affected by all the previous considerations of variable urine concentration, reactivity of metabolites, and detection thresholds.

Difficulty with the Interpretation of **Urine Drug Concentrations**

• Though they generally trend towards lower values, the absolute concentrations of excreted compounds can vary and identification of "new use" is problematic.

• As the figure demonstrates, improved performance can be provided by normalizing drug levels to urine Cr.

 However, this is not common practice and firm guidelines have not been established.

Figure 1. Urinary cannabinoid levels of specimens taken on alternate days after last marijuana use. \Box - concentration of THC metabolite in ng/ml urine. Δ - THC metabolite concentration divided by the creatinine concentration expressed in ng metabolite/mg creatinine.

From NIDA Monograph: Urine Testing for Drugs of Abuse

Current versus Past Use

 6-monoacetylmorphine is highly specific for acute heroin use.

 Unconjugated opiates can generally be detected for up to 12 hours after use.

• In contrast, their conjugated counterparts can be detectable for days.

 Similarly, 'cocaine' (the actual parent compound) can be detected for 6 – 12 hours after use.

• The inactive cocaine metabolite, benzoylecognine, is detectable for days to weeks.

Narcotic Alkaloids TLC Plates

Phencyclidine

Amitryptiline

Nortryptiline

Quinine

Methadone

Codeine

Morphine

 ω

Amphetamine & MDA

21 22 23 24

Methamphetamine & MDMA

Diphenhydramine

Chlor-trimeton

Pseudoephedrine

27

1 25 26

Ephedrine

Finding Unexpected Drugs

 Urine Thin Layer Chromatography (TLC): used for confirmation of DAU and also to "screen" for about 30 other drugs (when present in high or overdose concentrations).

 Urine Gas Chromatography/Mass Spectrometry (GC/MS): mainly for confirmation of DAU, also good for opiates, methadone, meperidine, "free" cocaine, PCP, and dextromethorphan.

• **HPLC of serum or urine by "TCA method":** good for a variety of drugs, especially TCAs, SSRIs, beta blockers, Ca-channel blockers, and benzodiazepines.

 Other specific drug assays intended for routine therapeutic drug monitoring.

Adulteration

• I don't know of any substance a person can ingest safely (i.e. non-toxic) that can 'mask' or interfere with drug screening immunoassays.

- **Except for a diuretic taken with lots and lots of water.**
- http://www.erowid.org/psychoactives/testing/testing.shtml
- However, there are LOTS of things one can add to a urine sample (*ex vivo*) that do interfere.
	- Strong acid, base, detergents (bathroom soap is #1), or any potent protein denaturant (after a 1:40 dilution).
	- **Can also buy "clean urine" online.**
- Basis for detection of an adulterated specimen is either to
	- test directly for the adulterant or
	- test if chemical characteristics of urine exceed physiologic limitations

Specimen Validity Testing

- 1. Temperature measured immediately after void
	- Should be between $32 38$ °C (90 100 °F)
	- **Detects substitution with another urine sample**
- 2. $3 < pH < 11$
	- Detects acids, bases, and detergents (often change pH)

3. Concentration

- A urine Cr < 2 mg/dL and a specific gravity < 1.001 is considered *inconsistent* with human urine.
- A urine Cr < 20 mg/dL and a specific gravity < 1.003 is considered overly *dilute*. May want to request a second, hopefully more concentrated, sample.
- 4. Specific additives monitored in forensic settings
	- Nitrites, Chromium, Peroxidase, Halogens, Glutarldehyde

Chromatographic Techniques are Modular

Preparation

$Sample \rightarrow Chromatography \rightarrow Detection$

- cell lysis
- protein precipitation
- filtration
- concentration
- liquid-liquid extraction
- solid phase extraction
- **hydrolysis**
- derivitazation

- gas chromatography
	- packed column
	- **capillary**
- **liquid**
	- chromatography
		- reverse phase
		- normal phase
		- ion-exchange
		- affinity
		- size exclusion
- thin layer/paper

- UV/Vis absorption
- infrared absorption
- flame ionization
- **electrochemical**
- fluorescence
- light scattering
	- nephelometry
	- turbidometry
- **Mass Spectrometry**

Specificity is Also Modular

Sample Prep **Chromatography Detection**

Cumulative Specificity of Method

MS/MS

Potential Preparative Steps

- Cell lysis or tissue homogenation
- Removal of Soluble Protein
	- **precipitation**
	- **filtration**
- Extraction
	- **single step liquid-liquid extraction**
	- multiple step liquid-liquid extraction ("back-extraction")
	- **Solid phase extraction**
- Chemical Modification
	- derivatization for increased volatility
	- chemical or enzymatic hydrolysis of glucuronide
- Concentration
	- **evaporation**

Protein Precipitation

- Generally performed chemically:
	- Organic solvents (acetone, acetonitrile, methanol)
	- Zinc sulfate in methanol (pH 7)
	- 5-sulfosalicylic acid in methanol (pH 1-2)
	- Perchloric or trichloroacetic acid
	- **Sodium tungstate in sulfuric acid**
	- Ammonium sulfate in HCl, heated
- Many lyse RBCs and can be used for whole blood analysis (e.g. zinc sulfate in methanol for immunosuppressants).
- Major concern is potential "trapping" of protein-bound drug in the precipitate.
	- Needs to be tested for empirically, i.e. hard to predict.
	- Can sometimes be extracted by washing the precipitate, but not always reproducible. Use of an internal standard can help.

Protein Filtration

- Uses a nitrocellulose (or equivalent) filter to specifically retain proteins greater than a given size (generally 3000 daltons). Most commonly, the solution is "pushed" through the filter using centrifugation.
- Separates "protein-free" from "protein-bound" drug. Used to get "free" drug concentrations.
- Note that the ratio of free/bound drug is NOT changed during the procedure (as long as you don't do a wash step); therefore, measured concentration of free drug is accurate.
- Generally requires about 1 ml of plasma/serum to get about 0.1 ml of protein-free filtrate.

Organic Extraction

- Most "drugs" are hydrophobic in nature and have greater solubility in organic phases than in aqueous solution.
	- Note that a majority (but not all) of the physiologic components of plasma and urine (protein, carbohydrates, electrolytes) are highly water soluble and are not extracted into an organic phase.
- The "organic phase" can be another liquid (e.g. hexane) or a solid, generally in the form of a column packed with polymer-coated beads.
- Organic extraction can be selective because the aqueous solubility of many drugs are pH dependent.

Sample Preparation for GC/MS

Step 1: "Hydrolysis"

- add β -glucuronidase to 1.0 ml of patient urine
- incubate at 65 °C for 3 hours
- centrifuge to remove debris after cooling to room temperature

Step 2: "Extraction"

- add 10 μ of internal standard solution to each sample.
- add 0.5 of 100 mM phosphate buffer at pH 6.0 (check pH and adjust)
- run each sample over a pre-washed solid-phase extraction column
- wash column extensively with aqueous phosphate buffer
- acidify with 0.1 N HCl and elute with methanol

Step 3: "Concentration"

• evaporate methanol by blowing dry nitrogen over sample

Step 4: "Derivatization"

- add 75 μ of MSTFA and heat at 70 °C for 20 minutes
- volume remaining after derivatization is transferred to autosampler for injection

Chromatographic Components

Each flavor of chromatography is best understood by breaking it down into modular components:

- 1) Sample "loading"
- 2) The "mobile phase" during separation.
- 3) The "stationary phase" during separation.

Separation of individual sample components is always based on their *relative affinity* for the *mobile* versus the *stationary* phases.

Because some molecules have higher affinity for the stationary phase, they will pass through the column *slower* than others and, therefore, will be separated from each other (we say they have been "retained" by the column).

Separation of Molecules by Chromatography

After injection, all molecules start out overlapping.

Due to varying relative affinity for the stationary versus the mobile phases, individual molecules begin to separate.

As the different molecules elute off of the column, they are detected as resolved "peaks".

Relative Retention Times

- During separation, the *absolute* rates/times for movement of molecules are not always reproducible.
- For example, columns can get dirty, decreasing the amount of stationary phase available for interaction with molecules. This is equivalent to shortening the length of the column. There can also be variability in the timing of injection.
- However, such perturbations should affect the rates of *all* molecules in the same way. Therefore, their *relative* rates/times are usually highly reproducible (selection of an appropriate *internal standard* is critical for this reason).
- The "*relative retention time*" (RRT) is defined as the detection time for a individual peak divided by the detection time for a known *internal standard*. RRTs are characteristic and reproducible (but not always 100% specific) identifiers of individual molecules.
- Note that sometimes a "corrected retention time" is reported where the absolute retention time of an analyte is adjusted according to the variation in the retention time of the internal standard compared to a control sample:

 $CRT_{analyte} = RT_{analyte} * (RT_{std} / RT_{std,control})$

Quantification of Drug Concentrations

- Peak "area" generally correlates with the amount of drug loaded onto a column and, thus, the original drug concentration.
- However, there can be sample-to-sample variation due to extraction efficiency, loading volumes, detection efficiency, etc.
- Again, the *internal standard* is utilized to correct for variations.
	- Similar to the relative retention time, a *relative peak intensity* is defined and related to drug concentration.
	- Variations in the peak area are not always similar for all molecules (e.g. some molecules may have a lower extraction efficiency due to proteinuria and others may not; it is important that the internal standard shares the same *susceptibility* to interferences or variations in efficiency as the analyte).
	- Therefore, the internal standard is chosen to be chemically similar to the analyte of interest to best correct for variations.
	- However, adequate similarity is *not* easy to predict or establish.
	- Extensive validation is ultimately necessary to satisfy the rigor of your assay. Need to test all anticipated interferences and also un-expected variabilities using "real" patient samples, either with a large correlation study, with a gold standard method and/or with addition/recovery studies.

Protocol for Quantification of Analyte Concentration Based Upon a Calibration Curve

- A known amount of an internal standard is added to every sample (including controls and calibrators) before any other preparative step.
- All samples are brought through the identical preparative steps, separated by a chromatographic method and quantitatively detected.
- The relative peak intensities are measured for a series of calibrators with a fixed amount of internal standard and varying amounts of a known analyte. These relative peak intensities are fit to an equation, generally linear, to define a *calibration curve*.
- Similarly, the relative peak intensities of the unknown samples are calculated and related to the *calibration curve* to quantify the concentration of the analyte (drug) in the original clinical sample.

Totals

 $\sim \zeta$

40491

 2.00 CAL $\,$

Totals

62187

3.00 CAL

÷

Totals

105292

5.00 CAL

Totals

232682

 $\langle \cdot \rangle$

11.00 CAL

 f^{\prime} $\gamma_{\rm eff}$

EZChrom Elite **Calibration Report**

Amiodarone (applied biosytem) Average RF: 0.749301 RF StDev: 0.0393945 LSQ Weighting: None Scaling: None Replicate Mode: Replace Fit Type: Linear $y = 0.767319x + 0$ Goodness of fit (r^2) : 0.999296

RF %RSD: 5.2575 Force Through Zero: On

Peak: Amiodarone -- ISTD

Page 1 of 1

EZChrom Elite Calibration Report

Desethyl (applied biosytem) RF StDev: 0.0462009 Average RF: 0.835262 LSQ Weighting: None Scaling: None Replicate Mode: Replace Fit Type: Linear $y = 0.850619x + 0$ Goodness of fit (r^2): 0.999008

Peak: Desethyl -- ISTD

RF %RSD: 5.5313

Force Through Zero: On

Page 1 of 1

Totals

32979

1.00

 $1 - 1$

Sample ID: HC Filename: C:\EZChrom Elite\DATA\012604A07 Method: C:\EZChrom Elite\METHODS\amiodarone.met 1/26/04 12:18:13 PM Acquired: Printed: 1/26/04 12:24:40 PM

Rel. Ret. Time for $Amiodarone =$ $2.75/4.46=$ 0.62

177898

8.38

 τ

Sample ID: 8489 C:\EZChrom Elite\DATA\012604A100 Filename: C:\EZChrom Elite\METHODS\amiodarone.met Method: Acquired: 1/26/04 2:59:04 PM Printed: 1/26/04 3:04:41 PM

Rel. Ret. Time for Amiodarone = $2.82 / 4.59 = 0.61;$ agrees with standard and therefore confirms identity…

Calibration curve for Amiodarone

Although, the computer fits the measured relative peak intensity to this curve mathematically, visual inspection clearly identifies the correct concentration of amiodarone.

Modern Mass Spectrometers are also Modular

Molecular Ionization Method/Device

Sequential Array of One or More Mass Analyzers

- 1. Electron Ionization (EI)
- 2. Chemical Ionization (CI)
	- **APCI**
- *3. Electrospray*
- 1. Quadrupole
- 2. Ion Trap
- 3. Time-of-Flight (TOF)
- *4. Molecular*

Electrospray Ionization (ESI)

Quadrupole Mass Analyzer

LC-ESI-QQQ "Triple Quad LC/MS/MS"

Multiple "Modes" for QQQ MS

MS1 Scan (same as single quad)

Product Ion Scan

Precursor Ion Scan

Multiple/Selected Reaction Monitoring (MRM or SRM) Scan

Tacrolimus:

MS1 (A) and Product (B) Ion Scans

Chromatographic Traces for Tacrolimus and Ascomycin MRMs

Figure 2. Mass chromatograms for Tacrolimus (upper traces) and Ascomycin (lower traces) for (A) the lowest calibrator (3ng/mL) and (B) the patient with the lowest concentration of Tacrolimus (Z6143, $~\sim$ 4.5 $ng/mL)$

The Near Future

- Rapid "dilute and shoot" LC/MS/MS methods will replace immunoassays for detecting drugs of abuse in urine.
- **•** Advantages
	- **Lower Reagent Cost**
	- **More sensitive and more specific**
	- Molecule-specific reporting, not "class reactivity"
	- Option for a broad "screen"
	- **Confirmation testing no longer required**
- Disadvantages
	- **Expensive and complex instrumentation**
	- Possible issues with turn-around times